GlassScriptPhysician profile
Colton Kyle Johnston
NPI 1003376328
$5,252.84
in general payments reported to CMS, 2019-2025
25 companies · $1,165 in 2025
The $1,165 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $852 · 2022: $360 · 2023: $1,193 · 2024: $1,683 · 2025: $1,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,971 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,971.14 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $980.55 | 2022-2025 | Verquvo, Winrevair |
| Actelion Pharmaceuticals US, INC. | $863.33 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Novartis Pharmaceuticals Corporation | $644.23 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $496.94 | 2021-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $377.14 | 2021-2025 | Lifevest |
| Amgen INC. | $334.90 | 2021-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $303.63 | 2021-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.35 | 2021-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $198.04 | 2021-2025 | |
| Pfizer INC. | $127.82 | 2023-2025 | |
| Amarin Pharma, INC. | $109.96 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $96.38 | 2021-2023 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $78.51 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $60.42 | 2023-2024 | Inpefa |
| Philips North America LLC | $54.00 | 2023-2024 | (Cm9) Amb Mon & Diag Und |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $47.43 | 2022-2024 | Linq II |
| Esperion Therapeutics, INC. | $39.52 | 2024-2025 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $34.96 | 2025 | Evkeeza |
| Scpharmaceuticals INC. | $34.82 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $27.20 | 2021 | |
| Sanofi-Aventis U.S. LLC | $24.37 | 2021 | |
| Kestra Medical Technology Services, INC. | $24.28 | 2025 | Assure Wcd |
| Daiichi Sankyo INC. | $16.60 | 2023 | Injectafer |
| Lilly USA, LLC | $16.44 | 2025 | Zepbound |
| Boston Scientific Corporation | $15.02 | 2023 | Watchman Flx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colton Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.